Hematologic Oncology | Specialty

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

February 7th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Study Confirms Long-Term Risk of Secondary Cancers in Pediatric Hodgkin Lymphoma Survivors

February 7th 2019

The relative risk of developing a solid subsequent malignant neoplasm remained elevated in survivors of childhood Hodgkin lymphoma, according to extended follow-up of more than 25 years from the Late Effects Study Group cohort.

FDA Approves Caplacizumab-yhdp in Acquired Thrombotic Thrombocytopenic Purpura

February 7th 2019

The FDA has approved the nanobody caplacizumab-yhdp in combination with plasma exchange and immunosuppression for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura, making it the first FDA-approved therapy indicated for this patient population.

Dr. Gordon Discusses Use of Checkpoint Inhibitors in Hodgkin Lymphoma

February 6th 2019

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, Northwestern University Feinberg School of Medicine, discusses the use of checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma.

Dr. Valent on Ongoing Research With Immunotherapy in Multiple Myeloma

February 6th 2019

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31st 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

Dr. Shah on Investigational Agents in CML

January 30th 2019

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses investigational agents in chronic myeloid leukemia (CML).

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin Lymphoma

January 29th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

The Current Unmet Needs in PTCL Treatment and Prospects

January 28th 2019

PTCL Treatment in the Community Setting

January 28th 2019

The Impact of Brentuximab Vedotin as PTCL Treatment

January 28th 2019

Treating Patients With CD30-Positive PTCL

January 28th 2019

An Overview of Peripheral T-Cell Lymphoma

January 28th 2019

PTCL Community Treatment and Future Advancements

January 28th 2019

The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 28th 2019

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

January 26th 2019

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the differences between investigational JAK inhibitors and ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

January 25th 2019

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment.